Showing 6321-6330 of 6635 results for "".
- Strathspey Crown's Alphaeon Acquires Toxin Developer Evolus, Inc.https://practicaldermatology.com/news/20131004-strathspey_crowns_alphaeon_acquires_toxin_developer_evolus_inc/2459443/Strathspey Crown Holdings, LLC has acquired Evolus, Inc. of Santa Barbara, California for an undisclosed amount. As part of the transaction, Strathspey Crown's wholly-owned subsidiary, Alph
- MELA Sciences Appoints Dr. Darrell Rigel as Chief Medical Advisor to Its Board of Directorshttps://practicaldermatology.com/news/20131001-mela_sciences_appoints_dr_darrell_rigel_as_chief_medical_advisor_to_its_board_of_directors/2459445/MELA Sciences, Inc., announced that Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at New York University, Langone Medical Center, has been appointed Chief Medical Advisor to the Company's Board of Directors. Dr. Rigel is a Clinical Profes
- Rosacea Concierge Offers Patient Support and Resourceshttps://practicaldermatology.com/news/20130924-rosacea_concierge_offers_patient_support_and_resources/2459453/Bayer HealthCare recently launched Rosacea Concierge, a new resource for the estimated 16 million people living with rosacea. The new, easy-to-navigate www.RosaceaConcierge.com includes information on rosacea in the form of video tutorials from a team of experts, including a der
- Precision Dermatology Names New CEOhttps://practicaldermatology.com/news/20130924-precision_dermatology_names_new_ceo/2459455/Robert J. Moccia has been appointed to the position of Chief Executive Officer at Precision Dermatology Inc. Mr. Moccia has led the introduction of a number of new strategies for growth since joining the company in January of this year. Mr. Moccia has 30 years of experience in dermatology, having mo
- Nucletron Introduces Esteya Electronic Brachytherapy for Treating Skin Cancerhttps://practicaldermatology.com/news/20130923-nucletron_introduces_esteya_electronic_brachytherapy_for_treating_skin_cancer/2459456/Nucletron, an Elekta company, recently launched Esteya, a new approach for treating patients with skin cancer. Esteya electronic brachytherapy mimics proven high dose rate (HDR) brachytherapy by bringing a small X-ray source very close to the cancerous site, enabling the local a
- Caliber Imaging & Diagnostics Introduces VivaScope 1500 Multilaser Systemhttps://practicaldermatology.com/news/20130910-caliber_imaging__diagnostics_introduces_vivascope_1500_multilaser_system/2459465/Caliber Imaging & Diagnostics, formerly Lucid, Inc., recently introduced the VivaScope 1500 Multilaser system, cellular imaging devices that give researchers the option of a painless, no
- Sensus Healthcare Appoints Dr. Mark Nestor as Clinical Directorhttps://practicaldermatology.com/news/20130830-sensus_healthcare_appoints_dr_mark_nestor_as_clinical_director/2459470/Mark Nestor, MD, PhD has been appointed as Clinical Director of Sensus Healthcare. Dr. Nestor will lead the company's efforts in the areas of training, education, and clinical research as Se
- Agenda Set for 2013 Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20130830-agenda_set_for_2013_cosmetic_surgery_forum/2459471/The 2013 Cosmetic Surgery Forum, taking place from December 5 – 7 at the Aria Resort and Casino in Las Vegas, has recently unveiled its agenda. According to course director Joel Schlessinger, MD, this year's meeting promises offer attendees a host of new sessions on injectables and newer methods of
- Speech Recognition Software Gets Boosthttps://practicaldermatology.com/news/20130828-speech_recognition_software_gets_boost/2459473/Spellex has released Spellex Dictation, a dictionary enhancement for Dragon NaturallySpeaking and other popular speech recognition software. Spellex says the dictation program allows users to dictate and correctly spell healthcare, legal, and BioScientific and engineering words and phrases.
- Roche's Erivedge OK'd in Canadahttps://practicaldermatology.com/news/20130827-roches_erivedge_okd_in_canada/2459474/Erivedge (vismodegib) was recently approved in Canada for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.